BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

21154

540596

ERIS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

ERIS LIFESCIENCES LIMITED performance

Today’s low

Today’s high

₹ 1417.10 ₹ 1459.90
₹ 1432.10

52 week low

52 week high

₹ 815.85 ₹ 1593.90
₹ 1432.10

Open Price

₹ 1454.50

Prev. Close

₹ 1464.80

Volume (Shares)

107682.00

Total traded value

₹ 1542.11

Upper Circuit

₹ 1757.70

Lower Circuit

₹ 1171.90

info

ERIS LIFESCIENCES LIMITED Share Price Update

As of the latest trading session, ERIS LIFESCIENCES LIMITED share price is currently at ₹ 1432.1, which is down by ₹ -32.70 from its previous closing. Today, the stock has fluctuated between ₹ 1417.10 and ₹ 1459.90. Over the past year, ERIS LIFESCIENCES LIMITED has achieved a return of 59.84 %. In the last month alone, the return has been 3.02 %. Read More...

ERIS LIFESCIENCES LIMITED fundamentals


  • Market cap (Cr)

    19,480.61

  • P/E Ratio (TTM)

    225.62

  • Beta

    0.62

  • Book Value / share

    189.24

  • Return on equity

    12.63%

  • EPS (TTM)

    6.35

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    1.78

info icon alternate text
  • Market cap (Cr)

    19,505.78

  • P/E Ratio (TTM)

    225.62

  • Beta

    0.62

  • Book Value / share

    189.24

  • Return on equity

    12.63%

  • EPS (TTM)

    6.35

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    1.78

info icon alternate text

ERIS LIFESCIENCES LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 390.00
Operating Expense 401.48
Net Profit 1.78
Net Profit Margin (%) 0.45
Earnings Per Share (EPS) 0.13
EBITDA 107.36
Effective Tax Rate (%) 70.48
Particulars SEP 2024 (Values in Cr)
Revenue 428.75
Operating Expense 396.34
Net Profit 28.10
Net Profit Margin (%) 6.55
Earnings Per Share (EPS) 2.06
EBITDA 148.44
Effective Tax Rate (%) 38.93
Particulars JUN 2024 (Values in Cr)
Revenue 449.17
Operating Expense 435.03
Net Profit 17.04
Net Profit Margin (%) 3.79
Earnings Per Share (EPS) 1.25
EBITDA 128.54
Effective Tax Rate (%) 36.46
Particulars MAR 2024 (Values in Cr)
Revenue 332.25
Operating Expense 319.94
Net Profit 39.51
Net Profit Margin (%) 11.89
Earnings Per Share (EPS) 2.90
EBITDA 99.78
Effective Tax Rate (%) 5.36
Particulars DEC 2023 (Values in Cr)
Revenue 315.96
Operating Expense 293.20
Net Profit 31.65
Net Profit Margin (%) 10.01
Earnings Per Share (EPS) 2.33
EBITDA 77.86
Effective Tax Rate (%) 8.63
Particulars MAR 2024 (Values in Cr)
Revenue 1454.75
Operating Expense 1192.70
Net Profit 299.72
Net Profit Margin (%) 20.60
Earnings Per Share (EPS) 22.04
EBITDA 488.65
Effective Tax Rate (%) 8.85
Particulars MAR 2023 (Values in Cr)
Revenue 1307.12
Operating Expense 911.07
Net Profit 398.01
Net Profit Margin (%) 30.44
Earnings Per Share (EPS) 29.27
EBITDA 522.38
Effective Tax Rate (%) 8.90
Particulars MAR 2022 (Values in Cr)
Revenue 1193.77
Operating Expense 786.18
Net Profit 417.19
Net Profit Margin (%) 34.94
Earnings Per Share (EPS) 30.70
EBITDA 512.99
Effective Tax Rate (%) 9.01
Particulars MAR 2021 (Values in Cr)
Revenue 1088.65
Operating Expense 729.93
Net Profit 350.61
Net Profit Margin (%) 32.20
Earnings Per Share (EPS) 25.82
EBITDA 427.30
Effective Tax Rate (%) 9.84
Particulars MAR 2020 (Values in Cr)
Revenue 1003.76
Operating Expense 711.36
Net Profit 291.27
Net Profit Margin (%) 29.01
Earnings Per Share (EPS) 21.23
EBITDA 370.32
Effective Tax Rate (%) 9.98
Particulars MAR 2024 (Values in Cr)
Book Value / Share 190.11
ROE % 16.61
ROCE % 12.05
Total Debt to Total Equity 0.76
EBITDA Margin 33.98
Particulars MAR 2023 (Values in Cr)
Book Value / Share 161.48
ROE % 18.23
ROCE % 16.68
Total Debt to Total Equity 0.23
EBITDA Margin 31.62
Particulars MAR 2022 (Values in Cr)
Book Value / Share 140.36
ROE % 23.29
ROCE % 24.45
Total Debt to Total Equity 0.03
EBITDA Margin 37.94
Particulars MAR 2021 (Values in Cr)
Book Value / Share 116.10
ROE % 24.72
ROCE % 26.81
Total Debt to Total Equity 0.00
EBITDA Margin 36.26
Particulars MAR 2020 (Values in Cr)
Book Value / Share 95.47
ROE % 24.24
ROCE % 24.80
Total Debt to Total Equity 0.07
EBITDA Margin 35.74
Particulars MAR 2024 (Values in Cr)
Book Value / Share 185.55
ROE % 12.63
ROCE % 9.98
Total Debt to Total Equity 0.60
EBITDA Margin 31.97
Particulars MAR 2023 (Values in Cr)
Book Value / Share 163.39
ROE % 19.23
ROCE % 19.94
Total Debt to Total Equity 0.08
EBITDA Margin 38.97
Particulars MAR 2022 (Values in Cr)
Book Value / Share 141.11
ROE % 23.88
ROCE % 25.68
Total Debt to Total Equity 0.00
EBITDA Margin 42.20
Particulars MAR 2021 (Values in Cr)
Book Value / Share 116.03
ROE % 24.39
ROCE % 26.48
Total Debt to Total Equity 0.00
EBITDA Margin 38.55
Particulars MAR 2020 (Values in Cr)
Book Value / Share 95.72
ROE % 23.72
ROCE % 24.21
Total Debt to Total Equity 0.07
EBITDA Margin 36.31
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1400.63
Total Assets 7048.83
Total Liabilities 7048.83
Total Equity 3222.03
Share Outstanding 136028280
Price to Book Ratio 4.53
Return on Assets (%) 5.56
Return on Capital (%) 6.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 58.45
Total Assets 3667.32
Total Liabilities 3667.32
Total Equity 2220.67
Share Outstanding 135992238
Price to Book Ratio 3.50
Return on Assets (%) 10.42
Return on Capital (%) 12.53
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 52.32
Total Assets 2272.13
Total Liabilities 2272.13
Total Equity 1908.20
Share Outstanding 135930197
Price to Book Ratio 4.88
Return on Assets (%) 17.87
Return on Capital (%) 20.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 38.27
Total Assets 1834.78
Total Liabilities 1834.78
Total Equity 1576.42
Share Outstanding 135780653
Price to Book Ratio 5.21
Return on Assets (%) 19.35
Return on Capital (%) 22.53
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 67.32
Total Assets 1552.30
Total Liabilities 1552.30
Total Equity 1296.33
Share Outstanding 135780653
Price to Book Ratio 3.85
Return on Assets (%) 19.10
Return on Capital (%) 22.87
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1296.73
Total Assets 5349.56
Total Liabilities 5349.56
Total Equity 2524.02
Share Outstanding 136028280
Price to Book Ratio 4.53
Return on Assets (%) 5.60
Return on Capital (%) 5.93
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 47.64
Total Assets 2783.65
Total Liabilities 2783.65
Total Equity 2221.88
Share Outstanding 135992238
Price to Book Ratio 3.50
Return on Assets (%) 14.29
Return on Capital (%) 15.68
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 46.10
Total Assets 2150.41
Total Liabilities 2150.41
Total Equity 1918.55
Share Outstanding 135930197
Price to Book Ratio 4.88
Return on Assets (%) 19.40
Return on Capital (%) 21.75
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 32.65
Total Assets 1754.80
Total Liabilities 1754.80
Total Equity 1575.46
Share Outstanding 135780653
Price to Book Ratio 5.21
Return on Assets (%) 19.97
Return on Capital (%) 22.25
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 64.95
Total Assets 1483.12
Total Liabilities 1483.12
Total Equity 1299.70
Share Outstanding 135780653
Price to Book Ratio 3.85
Return on Assets (%) 19.63
Return on Capital (%) 22.41
Particulars MAR 2024 (Values in Cr)
Net Income 431.23
Cash from Operations 586.75
Cash from Investing -1854.52
Cash from Financing 1379.77
Net change in Cash 11.26
Free Cash Flow 715.92
Particulars MAR 2023 (Values in Cr)
Net Income 404.64
Cash from Operations 368.94
Cash from Investing -982.10
Cash from Financing 688.02
Net change in Cash -2.33
Free Cash Flow 1210.36
Particulars MAR 2022 (Values in Cr)
Net Income 442.19
Cash from Operations 461.54
Cash from Investing -319.61
Cash from Financing -44.69
Net change in Cash 13.95
Free Cash Flow 582.58
Particulars MAR 2021 (Values in Cr)
Net Income 394.49
Cash from Operations 443.89
Cash from Investing -323.35
Cash from Financing -82.39
Net change in Cash -30.39
Free Cash Flow 469.65
Particulars MAR 2020 (Values in Cr)
Net Income 331.35
Cash from Operations 322.93
Cash from Investing 123.23
Cash from Financing -334.59
Net change in Cash 59.80
Free Cash Flow 474.21
Particulars MAR 2024 (Values in Cr)
Net Income 328.83
Cash from Operations 409.77
Cash from Investing -2491.89
Cash from Financing 2160.05
Net change in Cash 4.45
Free Cash Flow 758.81
Particulars MAR 2023 (Values in Cr)
Net Income 436.91
Cash from Operations 400.11
Cash from Investing -513.29
Cash from Financing 193.74
Net change in Cash 2.77
Free Cash Flow 711.37
Particulars MAR 2022 (Values in Cr)
Net Income 458.53
Cash from Operations 452.31
Cash from Investing -267.63
Cash from Financing -88.42
Net change in Cash 13.35
Free Cash Flow 505.59
Particulars MAR 2021 (Values in Cr)
Net Income 388.89
Cash from Operations 463.44
Cash from Investing -347.86
Cash from Financing -81.12
Net change in Cash -33.58
Free Cash Flow 489.06
Particulars MAR 2020 (Values in Cr)
Net Income 323.59
Cash from Operations 315.58
Cash from Investing 126.73
Cash from Financing -333.52
Net change in Cash 58.46
Free Cash Flow 464.30
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

ERIS LIFESCIENCES LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1432.10 -2.23 redarrow
red-green-graph indicator
5 Bearish
11 Bullish
  • 5 Days 1454.00
  • 26 Days 1393.90
  • 10 Days 1439.40
  • 50 Days 1359.60
  • 12 Days 1432.60
  • 100 Days 1331.30
  • 20 Days 1408.20
  • 200 Days 1267.30
1474.10 PIVOT

First Support

1447.70

First Resistance

1491.20

Second Support

1430.60

Second Resistance

1517.60

Third Support

1404.20

Third Resistance

1534.70

RSI

55.51

ADX

16.14

MACD

38.71

Williams % R

-33.78

Commodity Channel Index (CCI)

60.13

Date

2025-04-29

Week

91391.00

Same Day

102025.00

Month

62701.00

1 Year

0.62

3 Year

0.47

Over 1 Month

3.02%

down

Over 1 Year

59.84%

down

Over 3 Months

20.00%

down

Over 3 Years

28.43%

down

Over 6 Months

11.00%

down

Over 5 Years

23.38%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

ERIS LIFESCIENCES LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
18.65%
Promoter Holdings
54.84%
FII
8.42%
DII
18.06%
Promoter Shares(Pledge Percentage)
18.51%
Name Shares Category
Amit Indubhusan Bakshi 5.8335144E7 (42.84%) Shareholding of Promoter and Promoter Group
Lilac Investments Limited 1.1965882E7 (8.79%) Public Shareholding
Hdfc Small Cap Fund 1.0647333E7 (7.82%) Public Shareholding
Inderjeet Singh Negi 5939833.0 (4.36%) Shareholding of Promoter and Promoter Group
Rajendrakumar Rambhai Patel 5939834.0 (4.36%) Shareholding of Promoter and Promoter Group
Franklin India Smaller Companies Fund 4588705.0 (3.37%) Public Shareholding
Kaushal Kamleshkumar Shah 4468833.0 (3.28%) Shareholding of Promoter and Promoter Group
Uti-flexi Cap Fund 4083554.0 (3.0%) Public Shareholding
Hetal Rasiklal Shah 3000000.0 (2.2%) Public Shareholding
Bhikhalal Chimanlal Shah 2680000.0 (1.97%) Public Shareholding
Rakesh Shah 1975981.0 (1.45%) Public Shareholding
Amit Bakshi Foundation 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Inreal Ventures Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shah & Co. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mrudang Hiren Vakil (huf) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kaushal Kamlesh Shah (huf) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kamlesh Rasiklal Shah (huf) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pragnesh Bharatkumar Shah (huf) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pragnesh Bharatkumar 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pinky Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Alpana Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Bakulaben Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Bharatbhai Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Saanvi Kaushal Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Karmm Kaushal Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kajal Mrudang Vakil 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shilpaben Kamleshkumar Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kamleshkumar Rasiklal Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sweta Kaushal Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rajendrakumar Rambhai Patel Huf 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Hetal Bholabhai Patel 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Jagdish Bholabhai Patel 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ambaben Patel 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Dhyanvi Patel 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Parthiv Patel 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sanjay Rambhai Patel 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Chandrikaben Patel 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shardaben Rambhai Patel 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Parul Patel 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Tresna Foundation 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Cinta Medtech Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
-Çÿhappynings Lifeskills LlpGÇÖ Earlier Known As -Çÿfootlights Theaters LlpGÇÖ 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Indubhushan Huf 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Eris Lifesciences Private Limited Group Gratuity Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Eris Foundation 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Horizon Blue Ventures Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Amit Bakshi (huf) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Amit Somnat Mehrotra 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shashi Somnat 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Somnat Mehrotra 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Parv Amit Bakshi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Gauri Sachin Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Nira Indubhushan Bakshi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Indubhushan Bakshi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rangoli Amit Bakshi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Inderjeet Singh Negi Huf 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Upender Singh Rawat 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sandeepa Rawat 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rameshwari Devi Rawat 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shiv Chanran Singh Rawat 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Aditi Negi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Manvendra Singh Negi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Asha Rawat 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rekha Rawat 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rajeshwari Negi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sateshwari Devi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Suman Negi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sarthak Negi 100.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

ERIS LIFESCIENCES LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
11 Aug 2022 7.35 Interim 16 Aug 2022 Equity shares
05 Aug 2021 6.01 Interim 06 Aug 2021 Equity shares
13 Aug 2020 5.5 Interim 14 Aug 2020 Equity shares
19 Mar 2020 2.87 Interim 20 Mar 2020 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
11 Aug 2022 7.35 Interim 16 Aug 2022 Equity shares
05 Aug 2021 6.01 Interim 06 Aug 2021 Equity shares
13 Aug 2020 5.5 Interim 14 Aug 2020 Equity shares
19 Mar 2020 2.87 Interim 20 Mar 2020 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

ERIS LIFESCIENCES LIMITED Share Price

Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas.

The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. Its operations are supported by a distribution network of 22 Sales depots, 2,059 Stockists and more than 5,00,000 retail chemists.

In 2007, the company launched 'Eris' division focused on cardiology and diabetes segment. In 2008, the company launched 'Nikkos' division focused on gastroenterology and orthopedics segment. In 2009, the company launched 'Adura' division focused on cardiology and diabetes segment. In 2011, the company launched 'Montana' division focused on gynecology and pediatrics segment. In 2012, the company launched 'Inspira' division focused on cardiology segment.

In 2014, the company launched 'Victus' division focused on anti-diabetes segment. During the year, the company set up manufacturing facility at Assam. In 2015, the company launched 'Eris 2' division focused on pain management segment.

In 2016, the company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited). During the year, the company acquired 100% of the outstanding equity shares of Aprica Healthcare Private Limited and 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.

In 2017, the company acquired the trademarks UNION', REUNION' and BON UNION'.

Eris Lifesciences made its debut on the secondary equity market on 29 June 2017. The stock debuted at Rs 612 on BSE compared with the initial public offer (IPO) price of Rs 603.

In October 2017, Eris Lifesciences Ltd (Eris) acquired the entire shareholding of UTH Healthcare Ltd (UTH) for an all-cash consideration of Rs 129 million. UTH is largely engaged in the segments of obesity, diabetes, gestational diabetes mellitus, maternal nutrition, and cardio-vascular diseases. The acquisition provides Eris with a portfolio of products that complement its other offerings.

In December 2017, Eris Lifesciences Ltd (Eris) acquired the Indian branded formulations business of Strides Shasun Ltd (Strides) for an aggregate cash consideration of Rs 5000 crore. With this acquisition, Eris acquired the marketing and distribution rights for India for 130+ brands in the Neurology, Psychiatry, Nutraceuticals and Women Healthcare therapy areas. The Indian branded formulations business being divested by Strides had sales of Rs 181 crore for FY 2017.

During the year 2018, capital expenditure amounted to Rs 242.69 million. Additionally, consideration of Rs. 5,061.52 million was paid towards business acquisition.

During the year 2018, UTH Healthcare Limited and Eris Healthcare Private Limited (earlier known as Strides Healthcare Private Limited) became subsidiaries of the Company.

As on March 31, 2019, the Company has 5 subsidiaries out of which 4 are wholly owned subsidiaries.

During the year 2019, capital expenditure amounted to Rs 374.15 million. Additionally, consideration of Rs. 107.22 million was paid towards business acquisition.

In April 2019, the Company acquired the remaining shares of Kinedex Healthcare Private Limited, thereby making it a wholly owned subsidiary. It launched new business divisions, ErisART, Nutriverse, Aspire, Oncosciences, Filix, and Allure. A newly constructed facility for soft-gel was added in the year 2019 with total production capacity of 75 mn units. An extended facility has been included for supplements and Nutraceuticals with an additional capacity of 60 mn tablets, 41 mn capsules and 4 mn sachets. In December 2019, it launched Zomelis, after acquiring the trademark from Novartis.

As on March 31, 2020, the Company has 5 five wholly owned subsidiaries. During the year 2020, the Company has acquired the remaining shares of Kinedex Healthcare Private Limited, thereby making it a wholly owned subsidiary. Eris Healthcare Private Limited has incorporated subsidiary company 'Eris Pharmaceuticals Private Limited' on 2nd, June 2020. In Q3 FY 20, the Company launched Rariset, under their in-licensing agreement with Pharmanutra S.P.A for their patent protected Sucrosomial Iron.

As on March 31, 2021, the Company has 3 three wholly owned and 1 other than wholly owned subsidiaries. During the year 2021, two Companies namely Aprica Healthcare Limited and Eris Therapeutics Private Limited ceased to be subsidiaries of the Company. Eris Healthcare Private Limited, wholly owned subsidiary of the Company, had incorporated a subsidiary company 'Eris Pharmaceuticals Private
Limited' on 2nd June, 2020.

In FY'21. the Company strengthened portfolio with Gluxit, its Dapagliozin brand in the strategically important SGLT 2 segment launched in October'20. Eritel and LNBloc maintained ranks in their respective segments and made a debut in fast-growing anti-thrombotics segment through the launch of Rivalto, Rivaroxaban offering. It fortified portfolio with the launch of ZACD, an immunity-enhancing formulation and added Bricet to its portfolio. Of the top 4 Mother Brands - Serlift, Desval ER, Sonaxa and Levroxa while Serlift, and Desval ER maintained theirranks in their respective segments.

As on March 31, 2022, the Company has 3 wholly-owned subsidiaries and 2 other than wholly owned subsidiaries. In 2022, Eris Therapeutics Limited, wholly owned subsidiary of the Company, was incorporated on 23rd June, 2021. The Company's wholly owned subsidiary Eris M.J. Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited) issued fresh shares through private placement, pursuant to which Eris holding had 70% in Eris M.J. Biopharm Private Limited. It launched human insulin through subsidiary, Eris MJ Biopharm Ltd. In Q4 FY 22, it launched Xsulin in the forms of vials and cartridges.

During the year 2023, the Company acquired 100% stake in Eris Oaknet Healthcare Private Limited in 2023. It launched Glura, a DPP4 Inhibitor. In Jan'23, it acquired 9 Derma brands from Glenmark for Rs 3,400 million and in Mar'23, it acquired 9 Cosmetology brands from Dr Reddy's for Rs 2,750 million.

In 2022-23, Eris Healthcare Private Limited, a wholly owned subsidiary, demerged its Acquired Brands business to Aprica Healthcare Limited, a wholly owned subsidiary, through a Scheme of Arrangement effective December 23, 2022.

Parent organization Indian Private
NSE symbol ERIS
Founded 2007
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of ERIS Lifesciences Ltd?

Answer Field

The share price of ERIS Lifesciences Ltd for NSE is ₹ 1432.1 and for BSE is ₹ 1433.95.

What is the Market Cap of ERIS Lifesciences Ltd?

Answer Field

The market cap of ERIS Lifesciences Ltd for NSE is ₹ 1,94,80.61 Cr. and for BSE is ₹ 1,95,05.78 Cr. as of now.

What is the 52 Week High and Low of ERIS Lifesciences Ltd?

Answer Field

The 52 Week High and Low of ERIS Lifesciences Ltd for NSE is ₹ 1593.90 and ₹ 815.85 and for BSE is ₹ 1593.00 and ₹ 815.50.

How to Buy ERIS Lifesciences Ltd share?

Answer Field

You can trade in ERIS Lifesciences Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for ERIS Lifesciences Ltd?

Answer Field

The 1 year returns on the stock has been 59.84%.

What is the Current Share Price of ERIS Lifesciences Ltd?

Answer Field

ERIS Lifesciences Ltd share price is for NSE ₹ 1432.1 & for BSE ₹ 1433.95 as on Apr 30 2025 03:30 PM.

What is the Market Cap of ERIS Lifesciences Ltd Share?

Answer Field

The market cap of ERIS Lifesciences Ltd for NSE ₹ 1,94,80.61 & for BSE ₹ 1,95,05.78 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of ERIS Lifesciences Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for ERIS Lifesciences Ltd share is 225.62.

What is the PB ratio of ERIS Lifesciences Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for ERIS Lifesciences Ltd share is 189.24.

How to Buy ERIS Lifesciences Ltd Share?

Answer Field

You can trade in ERIS Lifesciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy ERIS Lifesciences Ltd Share on Bajaj Broking App?

Answer Field

To buy ERIS Lifesciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “ERIS Lifesciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|